Home / Health / Breakthrough Pill May Halve Breast Cancer Return Risk
Breakthrough Pill May Halve Breast Cancer Return Risk
19 Nov
Summary
- New drug giredestrant shows significant reduction in breast cancer recurrence.
- It targets ER-positive, HER2-negative breast cancer, the most common type.
- Giredestrant has shown fewer serious side effects than current treatments.
A groundbreaking new drug, giredestrant, has demonstrated significant potential in a late-stage clinical trial to reduce the recurrence of ER-positive and HER2-negative breast cancer. This form of cancer affects approximately 220,000 individuals annually in the US, and despite its commonality, it is notoriously difficult to treat, often leading to recurrence after standard hormonal therapies.
The experimental pill, developed by Swiss drugmaker Roche, works by targeting estrogen receptors on cancer cells, causing them to degrade and preventing further growth. Preliminary results from the phase three lidERA Breast Cancer trial indicate that giredestrant offers a statistically significant improvement in disease-free survival rates compared to current treatments that block estrogen.
Notably, giredestrant has also shown a favorable safety profile, with significantly fewer serious side effects reported compared to conventional therapies. Researchers believe this innovative drug may represent the first of its kind to show such substantial benefits post-initial treatment, offering a new, well-tolerated option for many breast cancer patients.
